White Paper

Pharma R&D Annual Review 2023 Supplement: New Active Substances Launched During 2022

Source: Citeline

By Ian Lloyd, Senior Director, Pharmaprojects at Citeline

GettyImages-1323841513 report

In a sequel to the Pharma R&D Report, respondents were asked exclusively about new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use, in addition to vaccines with novel antigenic components. It excluded an additional 83 first drug launches of reformulated or non-NAS moieties, biosimilars, and imaging agents. Instead, the report focused on first editions of genuinely new drugs and molecules, continuing the literary theme of the Pharma R&D Report for the year, and leaving other reprints aside.

Specifically, the latest report highlights the challenges of getting drugs published, such as imitating existing therapies, side effects, and poor efficacy, just like in the writing industry, where only 1% to 2% of manuscripts get published. The article stresses the importance of innovation and advancement in patient care and celebrates the successful launch of genuinely new and innovative drugs.

Access this white paper and explore the drugs that brought something genuinely new to the world of medicine in 2022 that just might have the potential to change the story of patients’ lives.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader